会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • 1-(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl)-.alpha.,.alpha
.
    • 1-(氨基烷基和氨基烷基氨基)羰基和硫代羰基)-α,α二芳基吡咯烷,哌啶和高哌啶乙酰胺和乙腈
    • US4812451A
    • 1989-03-14
    • US845148
    • 1986-03-27
    • James R. Shanklin, Jr.James M. Wilkinson, II
    • James R. Shanklin, Jr.James M. Wilkinson, II
    • C07D207/08C07D211/34C07D211/42C07D223/04A61K31/445
    • C07D207/08C07D211/34C07D211/42C07D223/04
    • Novel 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl-.alpha.,.alpha.-diaryl-pyrrolidine, piperidine and homopiperidineacetamides and acetonitriles having the formula: ##STR1## wherein; n is zero, one or two;X is oxygen or sulfur;Z is ##STR2## 10 or --(CH.sub.2); p is 0 to 5 inclusive with the proviso that when Z is ##STR3## p is at least one; Y is aminocarbonyl or cyano;Ar.sup.1 and Ar.sup.2 are 2, 3 or 4-pyrido, phenyl or substituted phenyl;R is hydrogen or loweralkyl;R.sup.1, R.sup.2 and R.sup.3 are hydrogen, cycloalkyl, loweralkyl, phenyl, substituted phenyl, phenylloweralkyl, and R.sup.2 and R.sup.3 taken with the adjacent nitrogen may form a heterocyclic residue, and diastereoisomers when possible and pharmaceutical salts; and the method and pharmaceutical compositions for treating cardiac arrhythmias therewith are disclosed.
    • 新颖的1- [(氨基烷基和氨基烷基氨基)羰基和硫代羰基-α,α-二芳基 - 吡咯烷,哌啶和高哌啶乙酰胺和具有下式的丙酮:其中; n为零,一或二; X是氧或硫; Z为10或 - (CH2); p为0至5,其条件是当Z为至少1时; Y是氨基羰基或氰基; Ar1和Ar2是2,3或4-吡啶基,苯基或取代的苯基; R是氢或低级烷基; R 1,R 2和R 3是氢,环烷基,低级烷基,苯基,取代的苯基,苯基低级烷基,与相邻的氮取代的R 2和R 3可以形成杂环残基,当可能时可以形成非对映异构体和药用盐; 并公开了用于治疗心律失常的方法和药物组合物。
    • 7. 发明授权
    • Lubricating oil additives
    • 润滑油添加剂
    • US06258761B1
    • 2001-07-10
    • US09329891
    • 1999-06-10
    • Richard M. LangeJames R. Shanklin, Jr.Jeffry G. DietzRichard YodiceNaresh C. Mathur
    • Richard M. LangeJames R. Shanklin, Jr.Jeffry G. DietzRichard YodiceNaresh C. Mathur
    • C10M15212
    • C10L1/236C08F8/30C10L1/221C10L1/238C10M159/12
    • A composition prepared by reacting (A) an esterified carboxy-containing interpolymer, said interpolymer being derived from at least two monomers, (i) one of said monomers being at least one vinyl aromatic monomer and (ii) the other of said monomers being at least one alpha, beta-unsaturated acylating agent, and having, before esterification, {overscore (M)}n determined by gel permeation chromatography ranging from about 8,000 to about 350,000, wherein from about 80% to about 99% of the carboxylic groups of said interpolymer are esterified, wherein from about 80 to about 100% of the ester groups contain from 8 to about 23 carbon atoms and from 0 to about 20% of the ester groups contain from 2 to 7 carbon atoms, with (B) a hydrocarbyl substituted carboxylic acid or functional derivative thereof wherein the hydrocarbyl group comprises from about 10 to about 400 carbon atoms, and (C) an amine having an average of more than 1 condensable N—H group, in any order or simultaneously, or with the preformed reaction product of (B) and (C) wherein said preformed reaction product has at least one condensable N—H group. Depending upon the relative amounts of reactant (A) and (B) used, a composition which acts primarily as a viscosity improver with dispersant properties (DVM) or primarily as a dispersant with viscosity improving properties (VMD) may be prepared or compositions with properties intermediate between these.
    • 一种组合物,其通过(A)含酯化的含羧基的互聚物,所述互聚物衍生自至少两种单体,(i)所述单体之一是至少一种乙烯基芳族单体和(ii)所述单体中的另一种在 至少一种α,β-不饱和酰化剂,并且在酯化之前,通过凝胶渗透色谱测定的超过(M)} n为约8,000至约350,000,其中约80%至约99%的羧基 所述互聚物被酯化,其中约80至约100%的酯基含有8至约23个碳原子,0至约20%的酯基含有2至7个碳原子,(B)烃基 取代的羧酸或其官能衍生物,其中烃基包含约10至约400个碳原子,和(C)平均大于1个可冷凝NH基团的胺,以任何顺序或同时或与 (B)和(C)的预成型反应产物,其中所述预成型反应产物具有至少一个可冷凝的N-H基团。 取决于所用的反应物(A)和(B)的相对量,可以制备主要作为粘度改进剂的分散剂性能(DVM)或主要作为具有粘度改进性能(VMD)的分散剂的组合物或具有性质的组合物 这些之间的中间。
    • 9. 发明授权
    • Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl)
aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory
and antiallergy agents
    • 芳基(烷基和亚烷基)-N - ((苯氧基和苯硫基)烷基)氨基杂环作为心血管,组织结构,抗分泌和抗过敏剂
    • US5070087A
    • 1991-12-03
    • US349247
    • 1989-05-08
    • Lina C. TengDavid A. WalshJames R. Shanklin, Jr.
    • Lina C. TengDavid A. WalshJames R. Shanklin, Jr.
    • A61K31/40A61K31/44A61K31/445A61K31/55
    • A61K31/40A61K31/44A61K31/445A61K31/55
    • A method of treating cardiac dysfunction, the effects of histamine, and gastric secretion excesses with aryl(alkyl and alkylene)-N-[(phenoxy and phenythio)alkyl]aminoheterocyclics corresponding to the formula: ##STR1## wherein Ar is phenyl or substituted phenyl; R is phenyl, substituted phenyl, pyridinyl or cycloalkyl; A is hydrogen, hydroxy, cyano, amido and amino; Q is --CH.sub.2 --, --CH--, or --CHOH--; d and n are zero or one and the dotted lines form double bonds consistent with the valence of carbon; p is zero, one or two; m is one to six inclusive; B is oxygen, nitrogen, sulfur, sulfinyl or sulfonyl; z is zero or one; l is zero or one; W is hydrogen, loweralkyl, halo, nitro, loweralkoxy or hydroxy; X is hydrogen, loweralkyl, halogen, loweralkoxy or hydroxy; Y is --CH(OH)CH.sub.2 OH, --CH(OH)C(O)OH, --C(O)C(O)OH, --C(O)CH.sub.2 OH,--C(O)C(O)OCH.sub.3, --C(O)C(O)OC.sub.2 H.sub.5, --CH.sub.2 C(O)OC.sub.2 H.sub.5, --CH(OH)C(O)OCH.sub.3, --CH(OH)C(O)OC.sub.2 H.sub.5 or --C(O)CH.sub.2 OC(O)CH.sub.3 ; and the pharmaceutically acceptable salts thereof; in addition to the above methods of treatment, compounds wherein (B).sub.z is oxygen are useful in a method of treating Gell and Coombs type 1 allergic responses in mammals.
    • 一种治疗心脏功能障碍的方法,组胺和胃分泌过度与芳基(烷基和亚烷基)-N - [(苯氧基和苯基)烷基]氨基杂环对应于下式:其中Ar是苯基或取代的苯基 ; R是苯基,取代的苯基,吡啶基或环烷基; A是氢,羟基,氰基,酰氨基和氨基; Q是-CH 2 - , - CH-或-CHOH-; d和n为零或一个,虚线形成与碳化合价一致的双键; p为零,一或二; m是一到六个包含; B是氧,氮,硫,亚磺酰基或磺酰基; z为零或一; l为零或一; W是氢,低级烷基,卤素,硝基,低级烷氧基或羟基; X是氢,低级烷基,卤素,低级烷氧基或羟基; Y是-CH(OH)CH 2 OH,-CH(OH)C(O)OH,-C(O)C(O)OH,-C(O)CH 2 OH,-C(O)C(O) C(O)C(O)OC 2 H 5,-CH 2 C(O)OC 2 H 5,-CH(OH)C(O)OCH 3,-CH(OH)C(O)OC 2 H 5或-C(O)CH 2 OC(O) 及其药学上可接受的盐; 除了上述治疗方法之外,其中(B)z是氧的化合物可用于治疗哺乳动物中凝胶和1型过敏反应的方法。